Английская Википедия:Diazoxide
Шаблон:Short description Шаблон:Drugbox Diazoxide, sold under the brand name Proglycem and others, is a medication used to treat low blood sugar due to a number of specific causes.[1] This includes islet cell tumors that cannot be removed and leucine sensitivity.[1] It can also be used in refractory cases of sulfonylurea toxicity.[2] It is generally taken by mouth.[1]
Common side effects include high blood sugar, fluid retention, low blood platelets, a fast heart rate, increased hair growth, and nausea.[1] Other severe side effects include pulmonary hypertension and heart failure.[1] It is chemically similar to thiazide diuretics.[1] It works by decreasing insulin release from the pancreas and increasing glucose release by the liver.[1]
Diazoxide was approved for medical use in the United States in 1973.[1] It is on the World Health Organization's List of Essential Medicines.[3][4] It is available as a generic medication.[5]
Medical uses
Diazoxide is used as a vasodilator in the treatment of acute hypertension or malignant hypertension.[6]
Diazoxide also inhibits the secretion of insulin by opening ATP-sensitive potassium channel of beta cells of the pancreas; thus, it is used to counter hypoglycemia in disease states such as insulinoma (a tumor producing insulin)[7] or congenital hyperinsulinism.
Diazoxide acts as a positive allosteric modulator of the AMPA and kainate receptors, suggesting potential application as a cognitive enhancer.[8]
Side effects
Diazoxide interferes with insulin release through its action on potassium channels.[9] Diazoxide is one of the most potent openers of the K+ ATP channels present on the insulin producing beta cells of the pancreas. Opening these channels leads to hyperpolarization of cell membrane, a decrease in calcium influx, and a subsequently reduced release of insulin.[2] This mechanism of action is the mirror opposite of that of sulfonylureas, a class of medications used to increase insulin release in type 2 diabetics. Therefore, this medicine is not given to non-insulin dependent diabetic patients.
The Food and Drug Administration published a safety announcement in July 2015 highlighting the potential for development of pulmonary hypertension in newborns and infants treated with this drug.[10]
See also
References
External links
Шаблон:Nonsympatholytic vasodilatory antihypertensives Шаблон:Other therapeutic products Шаблон:Ion channel modulators Шаблон:Ionotropic glutamate receptor modulators Шаблон:Portal bar
- ↑ 1,0 1,1 1,2 1,3 1,4 1,5 1,6 1,7 Шаблон:Cite web
- ↑ 2,0 2,1 Шаблон:Cite journal
- ↑ Шаблон:Cite book
- ↑ Шаблон:Cite book
- ↑ Шаблон:Cite book
- ↑ Шаблон:Cite journalШаблон:Closed access
- ↑ Шаблон:Cite journalШаблон:Open access
- ↑ Шаблон:Cite journalШаблон:Closed access
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite press release
- Английская Википедия
- Carbonic anhydrase inhibitors
- Vasodilators
- Potassium channel openers
- AMPA receptor positive allosteric modulators
- Kainate receptor agonists
- Benzothiadiazines
- Sultams
- Chloroarenes
- World Health Organization essential medicines
- Wikipedia medicine articles ready to translate
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии